Maternal care for anti-D [Rh] antibodies, third trimester
ICD-10 O36.013 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, third trimester.
O36.013 refers to maternal care for women who have developed anti-D (Rh) antibodies during pregnancy, specifically in the third trimester. This condition arises when an Rh-negative mother is exposed to Rh-positive fetal blood, leading to the production of antibodies that can cross the placenta and affect the fetus. The presence of these antibodies can result in various fetal complications, including hemolytic disease of the newborn, fetal growth restriction, and fetal distress. Monitoring and management during this critical period involve regular ultrasounds to assess fetal growth and well-being, as well as potential interventions such as intrauterine transfusions if severe anemia is detected. Maternal care also includes counseling regarding the risks associated with Rh incompatibility and the importance of follow-up care postpartum to prevent future complications in subsequent pregnancies.
Detailed records of maternal antibody status, fetal monitoring results, and any interventions performed.
Routine monitoring of an Rh-negative mother with a known history of anti-D antibodies, management of fetal growth restriction due to hemolytic disease.
Ensure accurate coding based on the severity of the condition and the specific interventions undertaken.
Comprehensive documentation of high-risk assessments, including ultrasound findings and any transfusion procedures.
Management of severe fetal anemia requiring intrauterine transfusion, monitoring of fetal distress in the context of Rh incompatibility.
Focus on the multidisciplinary approach to care and the need for precise documentation of all clinical findings.
Used for routine monitoring of fetal growth in mothers with anti-D antibodies.
Document the indication for the ultrasound and findings related to fetal growth and well-being.
Ensure that the ultrasound report includes details relevant to the management of anti-D antibodies.
Accurate coding of O36.013 is crucial for ensuring appropriate management of Rh incompatibility, which can lead to serious fetal complications. It also impacts reimbursement and the quality of care provided to the mother and fetus.
